Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 9 | Rare Historical Photos

FDA Halts Shipments from an Indian Plant That Supplied Sildenafil and Tadalafil to U.S. Compounding Pharmacies

FDA inspectors found residue, corrosion, and open-toed sandals at a Gujarat plant supplying U.S. compounding pharmacies. Shipments are halted.

Medical Daily · Sep 10

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily · Sep 10

A Tennessee Forensic Center Now Links 63 Deaths to a Synthetic Opioid Federal Officials Flagged in April

A Knox County forensic center has tied 63 deaths to cychlorphine, a synthetic opioid most laboratories are not equipped to test for.

Medical Daily · Sep 10

From analysis to the latest developments in health,
read the most diverse news in one place.

Dr. Sarah Daccarett on the Estradiol Patch Shortage and the Delivery Route That Isn't Affected

Women across the United States are being told their estradiol patches are unavailable. The Food and Drug Administration says there is no shortage. Both statements are, in a narrow sense, accurate, and the space between them is where patients are losing access to treatment.

Medical Daily · Sep 10

Erectile Dysfunction Drug Ingredients Sent to Compounding Pharmacies Recalled After Inspectors Found Filth at Indian Plant

FDA found filth and unverifiable test records at a plant supplying sildenafil and tadalafil to US compounding pharmacies. All its ingredients were recalled.

Medical Daily · Sep 10

A New Pancreatic Cancer Pill Lists at $39,800 a Month, and What Patients Actually Owe Varies Widely

Rasonque lists at about $477,600 a year. Here is what Medicare and commercially insured patients may actually pay for the new pancreatic cancer pill.

Medical Daily · Sep 10

A One Time CRISPR Infusion for Hereditary Angioedema Now Has a March Decision Date and No Advisory Panel

FDA accepted a priority review for lonvo-z, a one-time CRISPR treatment for hereditary angioedema, with a decision target of March 10, 2027.

Medical Daily · Sep 9

Read news from The Economist, FT, and more,
with one subscription

The Federal Mifepristone Safety Review Is Still Unfinished While Senators Press Its Three Approved Manufacturers on Oversight

FDA says its mifepristone safety study remains under analysis, and a Senate committee report faults the drug's three sponsors for prescriber oversight.

Medical Daily · Sep 9

Compounded Semaglutide and Tirzepatide Have Drawn More Than 1,700 Federal Problem Reports as Peptide Sales Climb

FDA logged 990 reports on compounded semaglutide and more than 730 on tirzepatide through May 31. Here is what buyers should ask.

Medical Daily · Sep 9

Fresenius Logged Leaking Dialysis Bags as Property Damage and Waited Eight Months Before Recalling the Affected Lots

FDA warning letter says Fresenius counted 35 leaking dialysis bag complaints, rated the harm as property damage, and recalled only after inspectors arrived.

Medical Daily · Sep 9

Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely seller

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 crore shares, or about 1% stake, for around Rs 638 crore at a floor price of Rs 385 per share, implying a discount of up to 1.9%…

The Economic Times · Sep 9

Sandoz bets big on biosimilars, aims to double group sales by 2035

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will…

The Economic Times · Sep 8

Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal

Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development comes alongside Biocon’s Brazil partnership for Pertuzumab under a 10-year programme.

The Economic Times · Sep 8

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This…

The Economic Times · Sep 8

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times · Sep 8

Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to…

Medical Daily · Sep 7

First Approved Alexander Disease Treatment Arrives with a List Price Above One Million Dollars Per Year

FDA approved Zanvastro for Alexander disease. Ionis set the list price at $285,000 per dose, or about $1.14 million a year at quarterly dosing.

The Economic Times · Sep 7

European shares subdued as surging crude sharpens focus on ECB rate path

European shares closed largely flat as higher oil prices and renewed US-Iran tensions raised inflation concerns, offsetting stronger euro zone economic data. Energy stocks gained, while Novartis fell after its cholesterol drug failed a key study. Investors also raised bets on further ECB rate hikes, including a possible December move.

The Economic Times · Sep 7

Exclusive | How Vijay Kedia turned a Rs 250 Neuland Labs bet into nearly 100x returns

Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the company’s promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with…

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Sep 6

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Medical Daily · Sep 4

Estrogen Patch Supply Draws Federal Response as Doctors and Lawmakers Press for an Official Shortage Declaration

FDA says it is working with all six estradiol patch makers as women struggle to fill prescriptions. The patches are still not on the shortage list.

MarketBeat · Sep 4

Revolution Medicines Got Its Breakthrough—What Moves It Next?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

The Economic Times · Sep 4

Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore

Fosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak, Axis, and ICICI Prudential Mutual Funds, while Gland Pharma shares closed higher at ₹2,932.40.

Medical Daily · Sep 4

Federal Money Moves Toward a Last Resort Antibiotic for Children as an FDA Decision Approaches in February

BARDA exercised a $36.9 million cefiderocol option under a contract that also funds a pediatric expansion now under FDA review.

Medical Daily · Sep 4

Fewer Than One in Four New Compounding Facilities Were Inspected, and Every Inspected Site Had Violations

A pharmacy journal study found that only 23% of newly registered 503B outsourcing facilities were inspected, and all had significant violations.

Medical Daily · Sep 4

Boston Scientific Pulls Unused Spinal Cord Stimulator Leads Tied to Fractures, but Implanted Devices Stay in Place

FDA labeled Boston Scientific's Infinion CX lead removal a Class I recall after 1,081 serious injuries. Implanted leads are not affected.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.